Comment
. 2009 Jun 2;72(22):1965; author reply 1965-6.
doi: 10.1212/01.wnl.0000349667.27301.c8.
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis
- PMID: 19487658
- DOI: 10.1212/01.wnl.0000349667.27301.c8
Item in Clipboard
Comment
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis
Neurology.
.
No abstract available
Comment on
-
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.Neurology. 2008 Oct 28;71(18):1390-5. doi: 10.1212/01.wnl.0000319698.40024.1c. Epub 2008 Jun 4. Neurology. 2008. PMID: 18525027 Clinical Trial.
Similar articles
-
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.Neurology. 2009 Sep 29;73(13):1078; author reply 1078-9. doi: 10.1212/WNL.0b013e3181ab6e08. Neurology. 2009. PMID: 19786703 No abstract available.
-
Atorvastatin does not alter interferon Beta-induced changes of serum matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in patients with multiple sclerosis.Arch Neurol. 2008 May;65(5):672-4. doi: 10.1001/archneur.65.5.672. Arch Neurol. 2008. PMID: 18474748 Clinical Trial. No abstract available.
-
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.Neurology. 2009 Jul 21;73(3):249; author reply 249-50. doi: 10.1212/01.wnl.0000349660.04686.85. Neurology. 2009. PMID: 19620618 No abstract available.
-
Use of interferon-beta in the treatment of multiple sclerosis.Adv Neurol. 2006;98:257-71. Adv Neurol. 2006. PMID: 16400838 Review. No abstract available.
-
Atorvastatin.Br J Hosp Med. 1997 Oct 1-14;58(7):333-6. Br J Hosp Med. 1997. PMID: 9509055 Review. No abstract available.
Cited by
-
Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.Neurol Ther. 2024 Apr;13(2):283-322. doi: 10.1007/s40120-023-00565-7. Epub 2024 Jan 11. Neurol Ther. 2024. PMID: 38206453 Free PMC article. Review.
-
Importance of Apolipoprotein A-I in Multiple Sclerosis.Front Pharmacol. 2015 Nov 20;6:278. doi: 10.3389/fphar.2015.00278. eCollection 2015. Front Pharmacol. 2015. PMID: 26635608 Free PMC article. Review.
-
Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis.J Neuroinflammation. 2011 Oct 4;8:127. doi: 10.1186/1742-2094-8-127. J Neuroinflammation. 2011. PMID: 21970791 Free PMC article.
-
Neurodegeneration in multiple sclerosis involves multiple pathogenic mechanisms.Degener Neurol Neuromuscul Dis. 2014 Mar 12;4:49-63. doi: 10.2147/DNND.S54391. eCollection 2014. Degener Neurol Neuromuscul Dis. 2014. PMID: 32669900 Free PMC article. Review.
-
The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: enthusiasm lost too soon?CNS Neurosci Ther. 2010 Dec;16(6):362-73. doi: 10.1111/j.1755-5949.2010.00179.x. CNS Neurosci Ther. 2010. PMID: 20626428 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
